NCT06775730View on ClinicalTrials.gov

A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

April 3, 2025

Study Completion Date

April 3, 2025

Conditions
Healthy Adult Female Participants
Interventions
DRUG

Ensitrelvir

Ensitrelvir will be administered per schedule specified in the arm description.

Trial Locations (1)

91206

Early Phase Clinical Unit Los Angeles, Glendale

Sponsors

Lead Sponsor

Shionogi
All Listed Sponsors
lead

Shionogi

INDUSTRY

NCT06775730 - A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants | Biotech Hunter | Biotech Hunter